PT
PTPI.US Petros Pharmaceuticals Inc
- Market cap
- USD 127K
- P/E
- 0.0x
- P/B
- 0.18x
- ROE
- -554.3%
- Dividend yield
- 766,216.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PTPI.US undervalued?
Graham numberThe Graham number of Petros Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Petros Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Petros Pharmaceuticals Inc yet.
Petros Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.
Full company profilePetros Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Petros Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 14.1M | 15.6M | 9.56M | 7.81M | 5.99M | 5.82M | 5.11M | 0.00 | 0.00 |
| Gross Profit | 3.57M | 2.86M | 5.51M | 6.21M | 3.70M | 4.19M | 3.90M | 0.00 | - |
| Operating Income | -7.65M | -19.3M | -17.3M | -18.0M | -19.9M | -13.6M | -17.7M | -4.64M | -4.03M |
| EBITDA | 374K | -14.0M | -12.3M | -1.74M | -13.7M | -4.21M | -10.8M | -4.50M | -3.95M |
| Net Income | -32.5M | -32.5M | -20.6M | -8.99M | -20.0M | -8.16M | -14.3M | 1.91M | -3.89M |
| EPS | -325 | -132 | -39 | -8.25 | -9.68 | -3.75 | -1.78 | 0.01 | -0.08 |
| Balance Sheet | |||||||||
| Total Assets | 66.9M | 58.4M | 69.9M | 67.4M | 32.4M | 33.8M | 10.6M | 5.16M | 3.55M |
| Total Liabilities | 68.6M | 50.3M | 52.4M | 31.8M | 15.7M | 21.3M | 18.1M | 2.29M | 2.84M |
| Shareholders' Equity | -1.68M | 8.02M | 17.5M | 35.5M | 16.7M | 12.5M | -7.47M | 2.87M | 701K |
| Cash & Short-term Investments | 2.79M | 2.15M | 17.1M | 23.8M | 9.43M | 13.3M | 3.71M | 5.14M | 3.49M |
| Total Debt | 47.2M | 13.7M | 7.81M | 405K | 9.88M | 8.28M | 7.39M | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | 8.02M | 2.53M | -15.3M | -11.9M | -12.8M | -7.63M | -2.60M | -6.73M | -3.30M |
| Capital Expenditure | 1.88M | 71.5K | 4.63K | 0.00 | 0.00 | 1.00 | 24.6K | 0.00 | 0.00 |
| Free Cash Flow | 6.15M | 2.46M | -15.3M | -11.9M | -12.8M | -7.63M | -2.63M | -6.73M | -3.30M |
| Ratios | |||||||||
| ROE | - | -405.4% | -117.8% | -25.3% | -120.0% | -65.4% | - | 66.7% | -554.3% |
| ROA | -48.5% | -55.7% | -29.5% | -13.3% | -61.8% | -24.2% | -134.6% | 37.1% | -109.6% |
| Net Profit Margin | -231.1% | -208.7% | -215.3% | -115.0% | -334.4% | -140.2% | -280.1% | - | - |
| Debt to Equity | - | 1.71x | 0.45x | 0.01x | 0.59x | 0.66x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Petros Pharmaceuticals Inc dividends
- Dividend yield
- 766,216.68%
- Forward dividend
- -
- Payout ratio
- 50,898.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 974M | 3.47 | 50,898.1% |
| 2024 | USD 1.29B | 161 | - |
| 2023 | USD 557M | 256 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on May 1, 2025.
Who owns Petros Pharmaceuticals Inc
- Insiders 25.59%
- Institutions 10.24%
- Public & others 64.18%
- Shares outstanding 42.4M
- Free float 28.9M
Top funds holding PTPI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 91.8K | 0.17% | +164.98% | Mar 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 31.8K | 0.06% | 0.00% | Mar 2025 |
| Fidelity Series Total Market Index | 16.4K | 0.03% | +1,311.72% | Mar 2025 |
| Northern Trust Extended Eq Market Idx | 510.00 | 0.00% | 0.00% | Mar 2025 |
| NT Ext Equity Mkt Idx Fd - L | 510.00 | 0.00% | 0.00% | Mar 2025 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 122.00 | 0.00% | +0.83% | Mar 2025 |
| NT Ext Eq Mkt Indx Fd DC Lend T4 | 122.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Eq Mkt Indx Fd DC Lend T3 | 122.00 | 0.00% | 0.00% | Dec 2024 |
| NT Ext Equity Mkt Idx Fd - NL | 118.00 | 0.00% | 0.00% | Mar 2025 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 92.00 | 0.00% | -2.13% | Mar 2025 |
| SSgA U.S. Total Market Index Strategy | 80.00 | 0.00% | +2.56% | Mar 2025 |
| Northern Trust Wilshire 5000 | 52.00 | 0.00% | 0.00% | Mar 2025 |
| NT Quality SCC US Fund - L | 51.00 | 0.00% | 0.00% | Mar 2025 |
| NT Quality Small Cap Core | 51.00 | 0.00% | 0.00% | Mar 2025 |
| Blackstone Alternative Multi-Strategy I | 35.00 | 0.00% | 0.00% | Dec 2024 |
Top institutions holding PTPI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 36.2K | 0.07% | -3.55% | Dec 2024 |
| Vanguard Group Inc | 31.8K | 0.06% | 0.00% | Dec 2024 |
| UBS Group AG | 13.0K | 0.02% | -70.62% | Dec 2024 |
| Advisor Group Holdings, Inc. | 200.00 | 0.00% | 0.00% | Dec 2024 |
| Group One Trading, LP | 79.00 | 0.00% | 0.00% | Dec 2024 |
| Bank of America Corp | 75.00 | 0.00% | +4.17% | Dec 2024 |
| Morgan Stanley - Brokerage Accounts | 19.00 | 0.00% | 0.00% | Dec 2024 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2025 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Dec 2024 |
Petros Pharmaceuticals Inc company profile
- Company name
- Petros Pharmaceuticals Inc
- Ticker
- PTPI.US
- Exchange
- USA Stocks
- Listed since
- Dec 2, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 973 242 0005
- Website
- petrospharma.com
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.
Petros Pharmaceuticals Inc management
3- Mr. Joshua N. SilvermanExecutive Chairman of the Board · born 1970
- Mr. Fady Boctor M.B.A.President & Chief Commercial Officer · born 1978
- Mr. Robert WeinsteinChief Accounting Officer, Principal Financial Officer & Principal Accounting Officer · born 1960